Pure Global AI
NCT06218602Recruiting

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

M.D. Anderson Cancer CenterPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
Fecal Microbiota Transplantation
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Feb 19, 2024
End date
Sep 10, 2026
Enrollment
40 participants
Primary outcome

Safety and adverse events (AEs)

Summary

To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at
 treating gut-related side effects of antibiotic treatment in participants who are receiving
 standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06218602
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06218602 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.